CTLA4 and non-small cell lung carcinoma: These immunotherapy‐based regimens included pembrolizumab, atezolizumab, cemiplimab, and dual immune checkpoint inhibitors (nivolumab plus ipilimumab [an anti‐CTLA‐4 antibody] ± chemotherapy), sintilimab plus chemotherapy and pembrolizumab plus chemotherapy, and atezolizumab plus chemotherapy ± bevacizumab (for non‐squamous NSCLC).2, 3, 4, 5, 6, 7, 8, 9, 10